The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Succinate dehydrogenase (SDH)‐deficient neoplasia
Abstract
The succinate dehydrogenase (SDH) complex is a key respiratory enzyme composed of four subunits: SDHA, SDHB, SDHC and SDHD. Remarkably, immunohistochemistry for SDHB becomes negative whenever there is bi‐alleic inactivation of any component of SDH, which is very rare in the absence of syndromic disease. Therefore, loss of SDHB immunohistochemistry serves as a marker of syndromic disease, usually germline mutation of one of the SDH subunits. Tumours which show loss of SDHB expression are termed succinate dehydrogenase‐deficient. In addition to loss of SDHB, tumours associated with SDHA mutation also show loss of SDHA expression. Fifteen per cent of pheochromocytoma and paraganglioma (PHEO/PGL) are associated with germline SDH mutation, and therefore SDH‐deficient. We recommend screening SDHB immunohistochemistry for all PHEO/PGL. SDH‐deficient gastrointestinal stromal tumours (GISTs) show distinctive features, including absent KIT proto‐oncogene receptor tyrosine kinase/platelet‐derived growth factor receptor A (KIT/PDGFRA) mutations [but positive staining for cKIT and DOG1], virtually exclusive gastric location, lobulated growth, multi‐focality, a prognosis not predicted by size and mitotic rate, frequent metastasis to lymph nodes and primary resistance to imatinib therapy. Thirty per cent are associated with SDHA germline mutation and 50% are associated with SDHC epimutation (post‐zygotic promoter hypermethylation) – the hallmark of the syndromic but non‐hereditary Carney triad (SDH‐ deficient GIST, SDH‐deficient paraganglioma and pulmonary chondroma). SDH‐deficient renal carcinoma is newly recognized under the World Health Organization (WHO) 2016 classification and shows vacuolated eosinophilic cytoplasmic and cytoplasmic inclusions. It is particularly associated with SDHB mutation, although SDHC and SDHA mutation occur. SDH‐deficient pituitary adenomas are recognized, but appear to be the least common SDH‐deficient neoplasm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Whole-genome landscape of pancreatic neuroendocrine tumours
Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., et al. (2017) · Nature · doi:10.1038/nature21063 · Cited by 999
Self-citationSDHA is a tumor suppressor gene causing paraganglioma
Burnichon, N., Brière, J.-J., Libé, R., Vescovo, L., Rivière, J., Tissier, F., Jouanno, E., Jeunemaitre, X., Bénit, P., Tzagoloff, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq206 · Cited by 650
Janeway, K. A., Kim, S. Y., Lodish, M., Nosé, V., Rustin, P., Gaal, J., Dahia, P. L. M., Liegl, B., Ball, E. R., Raygada, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009199108 · Cited by 628
Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes
Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1862 · Cited by 570
van Nederveen, F. H., Gaal, J., Favier, J., Korpershoek, E., Oldenburg, R. A., de Bruyn, E. M., Sleddens, H. F., Derkx, P., Rivière, J., Dannenberg, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70164-0 · Cited by 538
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
Comino-Méndez, I., Gracia-Aznárez, F. J., Schiavi, F., Landa, I., Leandro-García, L. J., Letón, R., Honrado, E., Ramos-Medina, R., Caronia, D., Pita, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.861 · Cited by 526
Miettinen, M., Wang, Z.-F., Sarlomo-Rikala, M., Osuch, C., Rutkowski, P., & Lasota, J. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182260752 · Cited by 363
Cited by
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Mitochondrial disorders of the OXPHOS system
Fernandez‐Vizarra, E., & Zeviani, M. (2021) · FEBS Letters · doi:10.1002/1873-3468.13995 · Cited by 305
Trpkov, K., Hes, O., Williamson, S. R., Adeniran, A. J., Agaimy, A., Alaghehbandan, R., Amin, M. B., Argani, P., Chen, Y.-B., Cheng, L., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00779-w · Cited by 258
Self-citationRegulation of succinate dehydrogenase and role of succinate in cancer
Dalla Pozza, E., Dando, I., Pacchiana, R., Liboi, E., Scupoli, M. T., Donadelli, M., & Palmieri, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.04.013 · Cited by 212
Lee, W. D., Mukha, D., Aizenshtein, E., & Shlomi, T. (2019) · Nature Communications · doi:10.1038/s41467-019-09352-1 · Cited by 70
Metadata
- Authors
- Gill, A. J.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2017-12-14
- Volume
- 72
- Issue
- 1
- Pages
- 106-116
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2774342415
- Cited by
- 256
- References
- 72
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Succinate dehydrogenase (SDH)‐deficient neoplasia. https://app.cochat.ai/papers/10.1111/his.13277
- The paper
- Gill, A. J. (2018). Succinate dehydrogenase (SDH)‐deficient neoplasia. Histopathology. https://doi.org/10.1111/his.13277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.